

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: May 12, 2026
PDL Changes Effective Date: July 1, 2026



The following changes will be made to the Preferred Drug List (PDL), effective July 1, 2026, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Antineoplastics Selected Systemic Enzyme Inhibitors	Ensacove (ensartinib hydrochloride)
Antiobesity Select Agents	Foundayo (orforglipron)
Antiobesity Select Agents	Zepbound (tirzepatide)
Bone Resorption Suppression and Related Agents, Others	Enoby (denosumab-qbde)
Bone Resorption Suppression and Related Agents, Others	Xtrenbo (denosumab-qbde)
Hypoglycemics, Incretin Mimetics/Enhancers	Mounjaro (tirzepatide)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Analgesics, Opioid-Short Acting	Xyvona (levorphanol)
Anticonvulsants, Adjuvants	perampanel
Antineoplastics Selected Systemic Enzyme Inhibitors	Komzifti (ziftomenib)
Antiretrovirals, NNRTIs	rilpivirine
Bronchodilators and COPD Agents, Anticholinergics and COPD Agents	ipratropium HFA
Calcium Channel Blockers, Long-Acting	Sdamlo (amlodipine)
Calcium Channel Blockers, Short-Acting	Cardamyst (etripamil)
Cephalosporins and Related Antibiotics (Oral), Cephalosporins Third Generation	cefixime tablet
Fibromyalgia/Neuropathic Pain Agents	milnacipran

**Mississippi Division Of Medicaid
 Provider Notice of Preferred Drug List Changes
 P&T Meeting Date: May 12, 2026
 PDL Changes Effective Date: July 1, 2026**



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Glucocorticoids (Inhaled)	beclomethasone
Immune Globulins	Gammagard ERC (immune globulin infusion (human))
Immune Globulins	Qivigy (immune globulin intravenous human-kthm)
Miscellaneous Brand/Generic, Familial Chylomicronemia Syndrome	Redemplo (plozasiran sodium)
Miscellaneous Brand/Generic, Miscellaneous	Myqorzo (aficamten)
NSAIDs, COX II Selective	Zybic (meloxicam)
NSAIDs, Non-Selective	Orudis (ketoprofen)
Ophthalmic Agents, Antibiotics	besifloxacin
Ophthalmic Agents, Antibiotic-Steroid Combinations	tobramycin/loteprednol
Stimulants and Related Agents, Long-Acting	Arynta (lisdexamfetamine)